Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen (BIIB) Q2 Earnings Beat, Shares Up

Biogen (BIIB) beat estimates both for earnings and sales in Q2. The company's oral MS drug Tecfidera sales decreased year over year.

    BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions

    Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.

      Madhu Goel headshot

      4 Biotech Bets to Watch as Industry Rebounds in a Month

      The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

        Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

        On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

          AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

          AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

            The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

            The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

              Mark Vickery headshot

              Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

              Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).

                Kevin Cook headshot

                Dopamine and the Weather, Part 2

                How technology changes human behavior and social rules, but not human nature and genetics???yet.

                  AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

                  AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

                    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

                    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

                      CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

                      CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.

                        Sweta Killa headshot

                        Biotech ETFs Surge on Biogen's Positive Drug Trial Result

                        Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

                          Stock Market News For Jul 9, 2018

                          Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday

                            Ryan McQueeney headshot

                            Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

                            Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

                              Biogen's Alzheimer Disease Candidate Succeeds in Phase II

                              Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

                                Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

                                Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise

                                    Mark Vickery headshot

                                    Top Analyst Reports for Johnson & Johnson, Biogen & General Motors

                                    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM).

                                      Sweta Killa headshot

                                      Sarepta Pharma Pushes Two Biotech ETFs to New Highs

                                      The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

                                        PTC Therapeutics' Spinal Muscular Atrophy Study Successful

                                        PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

                                          Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

                                          Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.

                                            Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                            Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                              Tracey Ryniec headshot

                                              Drug Stocks: The Next Hot Industry or Value Traps?

                                              These 5 stocks look dirt cheap but is it too good to be true?

                                                Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

                                                Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

                                                  Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                                                  Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.